Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study to evaluate the safety and efficacy of the combination of Imfinzi (durvalumab) and sacituzumab govitecan as a frontline treatment of patients with triple-negative breast cancer (TNBC) and urothelial cancer (UC)

Trial Profile

A phase 1/2 study to evaluate the safety and efficacy of the combination of Imfinzi (durvalumab) and sacituzumab govitecan as a frontline treatment of patients with triple-negative breast cancer (TNBC) and urothelial cancer (UC)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jul 2018 New trial record
    • 23 Jul 2018 According to an Immunomedics media release, Part one of the two-part Phase 1/2 studies will be co-funded by the two companies. Immunomedics will supply the study drug and AstraZeneca will utilize its existing clinical trial infrastructure to accelerate the enrollment of the sacituzumab govitecan and durvalumab combination.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top